Autres langues Pasithea Therapeutics Corp.

Actions

KTTA

US70261F2020

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 23/04/2024			Varia. 5j.	Varia. 1 janv.
7,09 ^USD	+4,88 %		-2,21 %	-4,19 %

29/03	Pasithea Therapeutics Corp. présente ses résultats pour l'exercice clos le 31 décembre 2023	CI
13/02	Pasithea Therapeutics annonce l'ouverture du recrutement aux États-Unis pour son essai de phase 1 de Pas-004	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	13/02
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004	13/02
Top Premarket Decliners	12/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position	09/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application	02/01
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients	02/01
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	28/12
Pasithea Therapeutics Announces Results from 2023 Annual Meeting	19/12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	11/12
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders	29/11
Pasithea Therapeutics Gets Positive Response From FDA Meeting for Rare Cancer Treatment	29/11
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development	29/11
Pasithea Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 51 Integrin for the Treatment of both Sporadic and Familial ALS	10/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pasithea Therapeutics Corp.

Actions

KTTA

US70261F2020

Autres langues

Filtres